Astra/Daiichi Trial Significantly Raises Breast Cancer Survival Rate
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.
Rare is a story this unequivocally positive. A "practice-changing" drug developed by AstraZeneca and Japanese pharma giant Daiichi Sankyo has produced trial results that could transform the treatment of late-stage breast cancer.
Data showed the drug, called Enhertu, doubled progression-free survival rates (the length of time a tumor is either stable or shrinks) compared to traditional chemotherapy, and could apply to a wider patient group than initially thought.
Source Fool.com
